导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.55% | 2021/4773 |
| 近一周 | -0.63% | 694/5458 |
| 近一月 | -1.72% | 1261/5421 |
| 近一季 | -1.68% | 1459/5205 |
| 近半年 | -6.32% | 3141/4920 |
| 近一年 | 4.47% | 1851/4361 |
| 近两年 | 31.55% | 2247/2954 |
| 近三年 | 18.45% | 1532/2253 |
| 成立以来 | 63.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.29% 1581/4961 |
7.98% 2640/5312 |
- - |
- - |
| 2025 | 6.51% 2958/4813 |
-5.13% 3260/3635 |
1.22% 2416/4076 |
10.71% 3255/4524 |
0.18% 2146/4813 |
| 2024 | 16.63% 786/3463 |
5.21% 389/2808 |
2.21% 375/3014 |
9.05% 2715/3129 |
-0.55% 1459/3463 |
| 2023 | 2.19% 328/2656 |
13.21% 274/2280 |
-0.55% 390/2385 |
-4.91% 1255/2515 |
-4.54% 1084/2655 |
| 2022 | -15.39% 419/2207 |
-12.60% 638/1919 |
3.61% 1123/2016 |
-10.25% 369/2113 |
4.10% 590/2208 |
| 2021 | 17.43% 231/1822 |
-0.16% 334/1255 |
4.98% 831/1330 |
9.64% 134/1466 |
2.19% 664/1822 |
| 2020 | 15.58% 782/1250 |
-10.64% 797/1028 |
4.87% 897/1067 |
9.76% 625/1164 |
12.37% 472/1184 |
| 2019 | 8.96% 735/1092 |
16.29% 675/754 |
-7.62% 567/804 |
-1.40% 653/850 |
2.87% 855/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证央企ETF VS. 长安沪深300非周期A(740101) |